Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Ultra Low Endotoxin

Name: Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Ultra Low Endotoxin
Brand: Puweituo Bio
SKU: KRASWT-HB002

Catalog numberKRASWT-HB002

HumanHEK293Molecule · MHCMolecular weight · 50.30 kDa

Product introduction

Recombinant Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide (accession: AAV53343.1(HLA-A*11:01) & P61769(B2M) &VVVGAGGVGK).

Product details

Molecular aliases: MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
Protein length: Gly25-Thr305
Expression system: HEK293
Molecular weight: The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result.
Purity: > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin: Less than 0.01 EU per μg by the LAL method.
Formulation: Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State: Lyophilized
Storage: -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution: Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data display

Bis-Tris PAGE Data — Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC Data — The purity of Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer is greater than 95% as determined by SEC-HPLC.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.

References

1.(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

加载中…

Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Ultra Low Endotoxin

Catalog numberKRASWT-HB002

HumanHEK293Molecule · MHCMolecular weight · 50.30 kDa

Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Ultra Low Endotoxin

Product introduction

Product details

Data display

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

Background

References

Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Ultra Low Endotoxin

Product introduction

Product details

Data display

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

Background

References